Biosortia Microbiomics

What Biosortia Microbiomics does

Biosortia Microbiomics is a private Columbus, Ohio-based biotechnology company founded in 2012 that develops microbiome-derived therapeutics for immuno-oncology and immunological applications. The company operates two integrated technology pillars: the Industrial-Scale Microbiome Mining (ISMM) platform, which physically harvests and concentrates natural microbial communities at kilogram-to-ton scale to access previously unculturable bioactive metabolites, and BiosortAI, a 13-stage AI/ML engine that applies predictive analytics, spectral matching, generative chemistry, and ADME/tox triage to prioritize molecules across the company's proprietary database of 110,000+ novel small molecules.

The company's therapeutic pipeline targets complex multi-factorial diseases using a 'gut-restricted polypharmacology' design logic — single molecules engineered to engage the full five-node gut-brain-immune axis while minimizing systemic exposure. The lead franchise BSP1-WL targets obesity and metabolic disease as a differentiated alternative to GLP-1 therapies, with parallel programs in IBD (non-systemic TNF modulation), CNS (peripheral gut-brain neuromodulation), neurorepair, oncology, pain, anti-infectives, biofilm disruption, and antiviral applications. As of May 15, 2026, the company had filed 25 provisional patents covering these programs.

Biosortia monetizes through a B2B partnership model targeting large/mid-size pharmaceutical companies, biotech firms, and academic research institutions. Revenue streams include licensing and co-development deals with upfront payments, milestones, and royalties; project-based discovery services delivered through BiosortAI; and access fees for its proprietary microbiome database and molecule library. The company has not publicly disclosed revenue or signed licensing deals, has received approximately $22M+ in cumulative funding (including a $6M ARPA-E grant in 2009, multiple government grants from DARPA, NIH, and US Air Force Research Lab, and angel/Keiretsu Forum rounds), and is led by founder-CEO Ross Youngs (75+ patents, R&D 100 Award recipient) alongside CSO Guy T. Carter, with healthcare investment banker Jaime Streator joining the board in April 2026.

Name

Biosortia Microbiomics

Legal name

Biosortia Microbiomics

Website

https://biosortia.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Biosortia Microbiomics is a Columbus, Ohio-based biotech founded in 2012 that develops microbiome-derived therapeutics for metabolic disease, IBD, CNS, oncology, and anti-infectives using its Industrial-Scale Microbiome Mining platform and BiosortAI discovery engine, monetizing through pharma licensing and project-based discovery services.

Ownership category

akta.pro rank

Product category

Microbiome Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB)

Keywords

• Microbiome drug discovery
• Natural product therapeutics
• AI drug discovery
• Gut-restricted polypharmacology
• Small molecule therapeutics

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D

Revenue model

1. Licensing and Co-development Deals: The company generates revenue through licensing its therapeutic candidates and discovery platform to pharmaceutical and biotech partners. Partners gain access to microbiome-derived starting points for drug development in exchange for upfront payments, milestone payments, and royalties.
2. Project-Based Discovery Services: BiosortAI offers project-based discovery services where pharma, biotech, academia, and research groups can engage Biosortia to search for hidden microbiome-derived molecules associated with specific biological activities or targets.
3. Database and Library Access: The company provides access to their proprietary microbiome database and molecule libraries for research purposes, enabling partners to leverage their unique chemical matter for discovery programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Biosortia Microbiomics operates a drug discovery platform that harvests and concentrates natural microbial communities at kilogram-to-ton scale via its proprietary Industrial-Scale Microbiome Mining (ISMM) technology, then applies its BiosortAI engine to identify, prioritize, and advance microbiome-derived small molecule therapeutic candidates. The company primarily licenses its therapeutic candidates and discovery platform to pharmaceutical and biotech partners, with a lead franchise (BSP1-WL) targeting obesity and metabolic disease through gut-restricted polypharmacology across the gut-brain-immune axis.

Product overview

Biosortia Microbiomics offers a unified platform combining Industrial-Scale Microbiome Mining (ISMM) technology with the BiosortAI discovery engine. ISMM harvests microbial communities at kilogram-to-ton scale to access previously hidden bioactive metabolites, while BiosortAI applies proprietary AI models to spectral matching, structure prediction, target mapping, and ADME/tox triage. The therapeutic pipeline centers on BSP1-WL for obesity/metabolic health (lead franchise), with expansion into IBD (TNF modulation), CNS (gut-brain neuromodulation), neurorepair, oncology, pain, anti-infectives, biofilm busting (macrocyclic protease-mimetics), and antiviral applications. The company operates a venture studio model and provides project-based discovery services to pharma, biotech, and academic partners.

Differentiator

Problem solved

Functional benefit

Brands

• BiosortAI: Project-based discovery offering for pharma, biotech, academia, and research groups seeking hidden microbiome-derived molecules associated with biological activity.
• Industrial-Scale Microbiome Mining (ISMM)

Products and services

• Industrial-Scale Microbiome Mining (ISMM) Platform The proprietary technology platform that harvests and concentrates natural microbial communities at kilogram-to-ton scale, enabling access to previously hidden bioactive metabolites and small molecules from unculturable microbiomes. The platform is licensed to pharmaceutical and biotech partners seeking differentiated drug discovery assets.
• BiosortAI Discovery Engine Project-based discovery offering combining industrial-scale microbiome access, deep proprietary datasets, and AI-guided triage to identify hidden microbiome-derived molecules associated with desired biological activities. Available to pharma, biotech, academia, and research partners seeking hidden microbiome-derived molecules for specific targets.
• BSP1-WL (Lead Obesity/Metabolic Franchise)
• Gut-Restricted TNF Modulation Program (IBD)
• Peripheral Gut-Brain Neuromodulation Program (CNS)
• Neurorepair and Regeneration Program
• Macrocyclic Protease-Mimetics (Biofilm Busting)
• Oncology Discovery Program
• Pain Therapeutic Program
• Anti-Infectives Program
• Ebola and Broad-Class Antiviral Program

Quantifiable outcome

• ~1.2% platform hit rate vs <0.1% for traditional synthetic library screening
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immunology and infectious disease. Directly comparable as a microbiome-derived therapeutic platform pursuing licensing and pharma partnerships in IBD and immuno-oncology.
• Seres Therapeutics: Pioneer in microbiome therapeutics with approved and clinical-stage assets (VOWST, SER-109). Comparable as a microbiome-derived drug discovery platform with licensing and partnership economics in the same therapeutic areas.
• Second Genome: Microbiome-based drug discovery company using microbial community biology to identify therapeutics for inflammatory and metabolic diseases. Directly comparable discovery model targeting similar indications with platform/partnering economics.
• Federation Bio: Microbiome therapeutics platform engineering defined consortia for metabolic, immune and oncology indications. Comparable as a platform-based microbiome drug discovery company pursuing pharma partnerships.
• Kallyope: Gut-brain axis drug discovery company combining microbiome science with proprietary chemistry and biology. Highly comparable given Biosortia's gut-brain-immune axis focus and polypharmacology approach in obesity and CNS.
• Microbiotica: UK-based microbiome therapeutics company using precision metagenomics to identify live bacterial therapeutics and small molecules. Comparable as a microbiome-derived discovery platform with pharma partnership model.
• Novome Biotechnologies: Microbiome therapeutics company engineering live biotherapeutics for hyperoxaluria, IBD and metabolic disease. Comparable platform biotech targeting microbiome-derived therapeutics with similar BD and licensing approach.
• Locus Biosciences: Clinical-stage biotechnology company developing engineered bacteriophage and microbiome-derived antimicrobials. Comparable as a microbiome-derived therapeutic platform, particularly for anti-infective applications.

Broad incumbents

• Recursion Pharmaceuticals: AI-driven drug discovery company using high-throughput biology and machine learning at scale. Comparable in the AI/ML-enabled discovery layer of Biosortia's BiosortAI engine and partnership-driven business model.
• Insitro: AI/ML-enabled drug discovery platform combining machine learning with high-throughput biology. Comparable as a platform company using proprietary data and AI to enable pharma discovery partnerships in metabolic and neurological disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biosortia-pharmaceuticals
• YouTubeyoutube.com/watch?v=xOv5lPKq1KQ
• Xx.com/Biosortia
• Facebookfacebook.com/Biosortia

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosortia Microbiomics